

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

SAFETY DATA SHEET

Section 1: Identification		
Material	Linezolid Tablets 600 mg	
Manufacturer	Hetero labs limited, Unit V, Polepally, Jadcherla,	
Distributor	Mahaboob Nagar -509 301, India. Camber Pharmaceuticals, Inc, Piscatway, NJ 08854	
Section 2: Hazard(s) Identification		
Section 2. Hazaru(8) Identification		
Classification according to Directive 67/548/EEC or 1999/45/EC	Carc.Cat.3; R40	
Hazard pictograms (CLP)		
	None	
CLP Signal word	Warning	
Hazard statements (CLP)	H302 - Harmful if swallowed H332 - Harmful if inhaled	
Precautionary statements (CLP)	P102 - Keep out of reach of children P103 - Read label before use P202 - Do not handle until all safety precautions have been read and understood P232 - Protect from moisture P233 - Keep container tightly closed P234 - Keep only in original container P235+P410 - Keep cool. Protect from sunlight P403 - Store in a well-ventilated place P410 - Protect from sunlight	
EUH phrases	EUH210 - Safety data sheet available on request	
Section 3: Composition/Information on Ingredients		
Composition/information on ingredients	CAS number	
Linezolid (Form- III)	165800-03-3	
Colloidal Silicon Dioxide (Aerosil-200) USP-NF	7631869	
Lactose Monohydrate USP - NF (Impalpable)	64044515	
Lactose Monohydrate USP - NF (Supertab 11 SD)	64044515	



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

Hypromellose, USP 2910 5cps (Methocel E5 LV Premium)	9004653	
Polacrilin Potassium, USP-NF (Kyron T 314)	39394-76-5	
Magnesium Stearate USP-NF	557040	
	Section 4: First-Aid Measures	
Section 4, First-aid measures		
Description of First Aid Measures	Eye contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately. Skin contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.	
	Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately	
	Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.	
Section 5: Fire-Fighting Measures		
Section 5, Fire-fighting measures		
Extinguishing Media	Extinguish fires with CO2, extinguishing powder, foam, or water.	
Special Hazards Arising from the Substance or Mixture		
Hazardous Combustion Products	Formation of toxic gases is possible during heating or fire.	
Fire / Explosion Hazards	Fine particles (such as dust and mists) may fuel fires/explosions.	
Advice for Fire-Fighters	During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.	
	Section 6: Accidental Release Measures	
Section 6, Accidental release m	neasures	
Personal Precautions, Protective Equipment and Emergency Procedures	Personnel involved in clean-up should wear appropriate personal protective equipment Minimize exposure.	
Environmental protection	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release	
Methods and Material for Containment and Cleaning Up		
Measures for Cleaning / Collecting	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.	



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

Additional Consideration for Large Spills	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.	
	Section 7: Handling and Storage	
Precautions for Safe Handling	Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment. Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.	
Storage	Store at 25°C; excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]	
Section 8: Exposure Controls/Personal Protection		
Engineering Controls: Personal Protective equipment Hands	 Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Impervious gloves are recommended if skin contact with drug product 	
Eyes	is possible and for bulk processing operations.Wear safety glasses or goggles if eye contact is possible.	
Skin Respiratory protection	 Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL. 	
	Section 9: Physical and Chemical Properties	
Physical State	Tablet	
Appearance	White to off-white crystalline powder.	
Molecular mass	337.346 g/mol	
Melting point	177.0-182.0 °C	
Description	Linezolid Tablets, 600 mg are white to off white, oval shaped, bevel edged, biconvex film coated tablets, debossed with 'I' on one side and '22' on other side.	



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.

Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250

e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

Availability 20 tablets in HDPE bottle NDC 31722-749-20

30 tablets in HDPE bottle NDC 31722-749-30

100 tablets in HDPE bottle NDC 31722-749-01

Unit-dose packages of 150 (15x10) tablets NDC 31722-749-31

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Lifetime studies in animals have not been conducted to evaluate the carcinogenic potential of linezolid. Neither mutagenic nor clastogenic potential was found in a battery of tests including: assays for mutagenicity (Ames bacterial reversion and CHO cell mutation), an in vitro unscheduled DNA synthesis (UDS) assay, an in vitro chromosome aberration assay in human lymphocytes, and an in vivo mouse micronucleus assay.

Linezolid did not affect the fertility or reproductive performance of adult female rats. It reversibly decreased fertility and reproductive performance in adult male rats when given at doses ≥ 50 mg/kg/day, with exposures approximately equal to or greater than the expected human exposure level (exposure comparisons are based on AUCs). The reversible fertility effects were mediated through altered spermatogenesis. Affected spermatids contained abnormally formed and oriented mitochondria and were non-viable. Epithelial cell hypertrophy and hyperplasia in the epididymis was observed in conjunction with decreased fertility. Similar epididymal changes were not seen in dogs.

In sexually mature male rats exposed to drug as juveniles, mildly decreased fertility was observed following treatment with linezolid through most of their period of sexual development (50 mg/kg/day from days 7 to 36 of age, and 100 mg/kg/day from days 37 to 55 of age), with exposures up to 1.7-fold greater than mean AUCs observed in pediatric patients aged 3 months to 11 years. Decreased fertility was not observed with shorter treatment periods, corresponding to exposure in utero through the early neonatal period (gestation day 6 through postnatal day 5), neonatal exposure (postnatal days 5 to 21), or to juvenile exposure (postnatal days 22 to 35). Reversible reductions in sperm motility and altered sperm morphology were observed in rats treated from postnatal day 22 to 35.

Section 12: Ecological Information

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Linezolid



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.

Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250

e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

Daphnia magna (Water Flea) OECD EC50 48 Hours > 100 mg/L

Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 Hours > 1.4 mg/L

Anabaena flos-aquae(Cyanobacteria) Algae OECD ErC50 72 Hours 1.5 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Linezolid

Activated sludge OECD EC50 > 1000 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Linezolid

Measured 6-8 Log D 0.55

Mobility in Soil: No data available

Section 13: Disposal Considerations

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

	Section 14: Transport Information
IATA/ICAO - Not Regulated	
IATA Proper shipping Name	: N/A
IATA UN/ID No	: N/A
IATA Hazard Class	: N/A
IATA Packaging Group	: N/A
IATA Label	: N/A
IMDG - Not Regulated	
IMDG Proper shipping Name	: N/A
IMDG UN/ID No	: N/A
IMDG Hazard Class	: N/A
IMDG Flash Point	: N/A
IMDG Label	: N/A
DOT - Not Regulated	
DOT Proper shipping Name	: N/A
DOT UN/ID No	: N/A



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA. Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250

e-mail:contact@heterodrugs.com URL:http//www.heterodrugs.com

DOT Hazard Class : N/A

DOT Flash Point : N/A

DOT Packing Group : N/A

DOT Label : N/A

Section 15: Regulatory Information

This Section contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Hetero labs limited shall not be held liable for any damage resulting from handling or from contact with the above product. Hetero labs limited reserves the right to revise this MSDS.